Targeting LRRK2 in Parkinson's disease: an update on recent developments

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Recent advancements in Leucine-Rich Repeat Kinase 2 (LRRK2) research include identifying interactors and developing kinase inhibitors.
• LRRK2 mutations are linked to Parkinson's disease (PD), highlighting the need for effective therapeutic targets.

Purpose of the Study:

• To review current LRRK2 research, focusing on mammalian models, interactors, and kinase inhibitors.
• To discuss potential alternative drug targets based on LRRK2’s non-kinase functions.

Main Methods:

• Review of recent literature on LRRK2 mammalian models for in vivo substrate validation.
• Analysis of reported LRRK2 interactors and their mechanisms.
• Overview of commonly used LRRK2 kinase inhibitors.

Main Results:

• Identification of LRRK2 substrates is key for developing new therapeutic strategies for PD.
• LRRK2 possesses non-kinase functions that may represent alternative drug target sites.
• Further studies are needed to understand the effects of LRRK2 kinase inhibition on its non-kinase functions and self-regulation.

Conclusions:

• Exploring LRRK2’s non-kinase functions could reveal novel therapeutic avenues for Parkinson's disease.
• Developing robust assays to measure LRRK2 inhibitor efficacy is essential.
• Testing therapeutic targets in both LRRK2 carriers and non-carriers is important due to similar disease phenotypes.